Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Widespread adaptation of liquid biopsy for the early detection of cancer has yet to reach
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …

Recently, many genome‐wide profiling studies provided insights into the molecular make‐
up of major cancer types. The deeper understanding of these genetic alterations and their …

Recent technological advances in the field of molecular diagnostics (including blood-based
tumor genoty**) allow the measurement of clonal evolution in patients with cancer, thus …

The aim of this review was to explore the status of urine sampling as a liquid biopsy for
noninvasive cancer research by reviewing used preanalytical parameters and protocols. We …

Simple Summary ctDNA is a small DNA fragment derived from tumor cells, which contains
tumor-related genomic information, such as mutation, methylation, microsatellite instability …

Purpose: ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in
real-time. We explored whether the quantitative percent change in ctDNA early after therapy …

Background: Colorectal cancer is one of the most common cancers worldwide and has a
high mortality rate following disease recurrence. Treatment efficacy is maximized by …

Precision medicine is now pivotal to design patients' specific treatment strategies with the
aim of prolonging progression and overall survival. In this regard, invasive tumor tissue …

Liquid biopsy is gaining significant attention as a tool for unveiling the molecular landscape
of tumor and holds great promise for individualized medicine for cancer. Cell-free DNA …